NEW YORK, March 16 (Reuters) – Roche’s Ashley Magargee, chief executive of its Genentech unit, said on Monday the company is striving to build a portfolio of obesity medicines that are both tolerable in terms of side effects and affordable.
“A lot of patients are dropping off therapy for various reasons,” said Magargee, speaking at the Reuters Pharma USA 2026 event in Philadelphia, pointing to long-term weight maintenance and combination therapies for people who are not responding to just one medicine as two areas of focus.
“How can you not just get these new medicines to patients, but also, how can you get an affordable portfolio of medicines to treat all the needs across the patient population now?” she said.
(Reporting by Michele Gershberg and Michael Erman; writing by Caroline Hume; Editing by Chizu Nomiyama)
